Keros Therapeutics
KROS | NASDAQ
$10.03
-$0.27 (-2.62%)
At close: Nov 16, 2026, 4:00 PM ET
$10.18
+$0.15 (+1.50%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Keros Therapeutics Company Profile
Company profile explainedCompany Profile
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Jasbir S. Seehra | President, Chief Executive Officer & Director |
| Esther Cho | Chief Legal Officer & Secretary |
| Annita Tanini | VP of Finance, Corporate Controller and Interim Principal Financial & Accounting Officer |
| Justin Frantz | Head of Investor Relations |
| Lorena Lerner | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 16, 2026 | EFFECT | Filing |
| Sep 11, 2026 | DEL AM | Filing |
| Sep 10, 2026 | S-3 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 20, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
Keros Therapeutics
| Country | United States |
| IPO Date | Apr 8, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 92 |
| CEO | Jasbir S. Seehra |
Contact Details
1050 Waltham Street Lexington,
Massachusetts 02421 United States
Stock Details
| Ticker Symbol | KROS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001664710 |
| CUSIP Number | 492327101 |
| ISIN Number | US4923271013 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove KROS